Mentice AB (MNTC) AI Stock Analysis

• Market Cap: kr531.83M
• Dividend Yield: N/A
• Average Volume (3M): 14.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 17.75%
• EPS Growth: 18.05%
• Country: SE
• Employees: 131
• Sector: Technology
• Sector Strength: 83
• Industry: Medical - Devices
• EPS (TTM): -1.09
• Shares Outstanding: 25,568,850
• 10 Day Avg. Volume: 11,704
• 30 Day Avg. Volume: 14,362
• PEG Ratio: -1.30
• Price to Book (P/B): 3.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 332.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: kr20.00 ▼(-3.38%Downside)

The overall score reflects challenges in profitability and valuation, despite some stability in the balance sheet and revenue growth. Technical indicators suggest bearish momentum, with the stock trading below key moving averages. The lack of dividend yield and a negative P/E ratio further impact the valuation negatively.

Mentice AB Business Overview & Revenue Model

Company Description

Mentice AB (MNTC) is a global leader in medical simulation solutions, specializing in the development of high-fidelity virtual reality-based training systems for healthcare professionals. The company focuses primarily on endovascular procedures, offering products that help medical practitioners enhance their skills and improve patient outcomes. With a strong emphasis on innovation, Mentice provides a range of simulators designed to replicate real-life surgical scenarios, thus aiding in the education and training of surgeons and medical students worldwide.

How the Company Makes Money

Mentice AB generates revenue through the sale of its medical simulation solutions, which include high-tech simulators for various endovascular procedures. The company's primary revenue streams are derived from direct sales to healthcare institutions, including hospitals, medical universities, and training centers. Additionally, Mentice offers subscription-based software licenses and maintenance contracts, providing ongoing technical support and updates for their products. The company also partners with medical device manufacturers to develop integrated training solutions, which can further contribute to its revenue. These collaborations enable Mentice to offer customized training modules that complement specific medical devices, thereby enhancing its value proposition to customers.

Mentice AB Financial Statement Overview

Summary

Mentice AB displays promising revenue growth, but its profitability and cash flow stability require improvement. The balance sheet is strong with low leverage, but performance fluctuations are a concern. The company should focus on enhancing operational efficiency to convert revenue growth into sustainable profits and cash flow.

Income Statement

Mentice AB has shown consistent revenue growth over the years, with a notable increase from 2023 to 2024. Despite the positive revenue trajectory, the company is struggling with profitability as indicated by negative EBIT and net income margins. The gross profit margin remains strong, suggesting cost management at the production level is effective, but operating expenses are impacting overall profitability.

Balance Sheet

The company maintains a healthy equity ratio, indicating a solid capital structure with a significant portion of assets financed by equity. The debt-to-equity ratio is low, reflecting limited leverage, which reduces financial risk. However, the company has experienced fluctuations in stockholders' equity, which could indicate instability in financial performance.

Cash Flow

Mentice AB shows a positive operating cash flow, which is a good indicator of cash generation from core business activities. However, free cash flow has seen volatility, and the free cash flow to net income ratio is not as robust as desired due to negative net income figures. The company needs to improve its cash flow stability to ensure sustainable financial health.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
291.81M	273.61M	217.95M	185.06M	137.50M
	Gross Profit
258.73M	236.38M	188.94M	149.92M	104.11M
	EBIT
-12.40M	-679.00K	-22.67M	-18.51M	-31.59M
	EBITDA
16.56M	28.87M	266.00K	1.44M	-3.90M
	Net Income Common Stockholders
-18.42M	-2.82M	-30.66M	-29.19M	-13.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
53.59M	59.12M	47.28M	12.70M	48.75M
	Total Assets
323.90M	322.53M	332.98M	261.90M	245.27M
	Total Debt
9.14M	9.56M	16.68M	14.70M	11.51M
	Net Debt
-44.45M	-49.56M	-30.61M	2.01M	-37.24M
	Total Liabilities
180.24M	163.55M	170.34M	125.02M	82.02M
	Stockholders Equity
143.66M	158.97M	162.63M	136.89M	163.25M
Cash Flow		Free Cash Flow
1.48M	29.53M	1.85M	-31.03M	5.20M
	Operating Cash Flow
17.92M	36.52M	14.91M	-5.13M	30.53M
	Investing Cash Flow
-16.44M	-16.18M	-32.28M	-25.90M	-24.97M
	Financing Cash Flow
-9.31M	-7.05M	48.99M	-5.78M	-3.98M

Mentice AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Positive. The current price of 20.7 is above the 20-day moving average (MA) of 16.94, above the 50-day MA of 18.90, and below the 200-day MA of 23.74, indicating a neutral trend. The MACD of 0.37 indicates Negative momentum. The RSI at 67.72 is Neutral, neither overbought nor oversold. The STOCH value of 96.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MNTC.

Mentice AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	€1.15B	35.49	10.11%	―	2.53%	-44.90%
Sector *	62 Neutral	$11.80B	10.37	-7.29%	2.91%	7.39%	-7.96%
INTEG.B	53 Neutral	€430.95M	―	-19.17%	―	-12.50%	-783.92%
SEDANA	52 Neutral	kr1.21B	―	-5.61%	―	13.66%	-139.90%
MNTC	49 Neutral	kr531.83M	―	-17.16%	―	17.75%	18.05%
ACARIX	46 Neutral	€255.30M	―	-88.97%	―	-0.61%	54.19%
BACTI.B	46 Neutral	€1.05B	―	-7.30%	―	23.51%	80.47%